	Name:
Location (City, State): Rochester, NY	DOB:
	Last Date of Infusion: New Start: \Box
Aduhelm® (aducanumab-avwa) Infusion Orders	
Diagnosis (please provide ICD-10 code in space provided):	
Alzheimer's Disease Other:	
	Other:
Hold infusion and notify provider for	
o Abnormal vital signs	
o No brain MRI results in chart (need MRI within one year of starting treatment, and prior to 7 th and 12 th infusion).	
 Signs of Amyloid Related Imaging Abnormalities (ARIA) as reported on MRI results 	
o New or worsening headache or altered mental status	
 Document measured weight at each appointment. Record vital signs before infusion, then every 30 minutes until patient discharge. 	
 If infusion-related reaction occurs, stop infusion follow Hypersensitivity Reaction Management Protocol 	
as clinically indicated.	
Pre-medications (to be administered once prior to infusion):	
☐Induction:	
Infusion 1 and 2 ⊠ Aduhelm 1r	ng/kg
Infusion 3 and 4 ⊠ Aduhelm 3r	ng/kg
Infusion5 and 6 ⊠ Aduhelm 6r	mg/kg
Infusion 7 and beyond ⊠ Aduhelm 10	Omg/kg
☐ Maintenance:	
☐ Aduhelm 10mg/kg x (current we	ight) kg= mg in
All doses to be mixed in 100 mL 0.9% sodium chloride and infused over a period of 60 minutes. Use a 0.2 or 0.22	
micron sterile, in-line, low-protein binding filter	
Frequency: All infusions administered every 4 weeks	
Observation Period: Monitor patient for hypersensitivity reinfusion. Record vital signs prior to discharge. Patient is required to stay for observation period follow Patient may sign Release of Responsibility Form after	ing every infusion.
To report suspected adverse reactions, contact Biogen at 1-833-425	5-9360 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Provider name (print):	Date:
Provider signature:	Time: